Trials / Recruiting
RecruitingNCT05412290
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Conditions
- B Cell Lymphoma
- Aggressive Lymphoma
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Lymphoma
- Follicular Lymphoma Grade 3
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mosunetuzumab | Mosunetuzumab is administered intravenously in a "step-up" dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following. |
Timeline
- Start date
- 2022-12-22
- Primary completion
- 2027-01-31
- Completion
- 2028-08-31
- First posted
- 2022-06-09
- Last updated
- 2025-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05412290. Inclusion in this directory is not an endorsement.